Interleukin 11 is already licensed for its effect in improving platelet count..., and it seems likely that thrombopoietin and its homolog, rh - PEG - MGDF, soon will be. ”
Jau ir licencēts interleikīns 11, kas spēj palielināt trombocītu skaitu organismā.., un, pēc visa spriežot, drīz licencēs arī trombopoetīnu un tā homologu, rh - PEG - MGDF. ”